| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9414eb8baa5e3ff1d70c9b21b4cdb1ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a6202d997a01dabcdb3a243e7ec16c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-121 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0474
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0491
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-06 |
| filingDate |
2015-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44e320f27247e4731c0b62d6399e8328
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1249fc0908338a59f7897dd48c415d81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9a4c8a4d69981d911d591c5f8d5530c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bffd64ba09a40d3539b9a41f164e551 |
| publicationDate |
2017-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2015323328-A1 |
| titleOfInvention |
Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells |
| abstract |
This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radionuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer. |
| priorityDate |
2014-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |